President, Chief Executive Officer, Director · EAGLE PHARMACEUTICALS, INC. (EGRX)

Scott Tarriff

A named executive officer of EAGLE PHARMACEUTICALS in every fiscal year CompBrief holds from FY2018 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$10,520,577

Salary $848,940Stock awards $9,011,197

FY2021: $6,471,521

1st of 3 named executive officers at Eagle Pharmaceuticals by FY2022 total.

3 named officers on file for EAGLE PHARMACEUTICALS, FY2022

Scott Tarriff’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 6 equity grants, each cited to its filing
  • EGRX’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how EAGLE PHARMACEUTICALS’s whole pay program stands against its peers

  • EAGLE PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on EGRX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 1, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Scott Tarriff’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Scott Tarriff compensation by year

EAGLE PHARMACEUTICALS Summary Compensation Table · all 5 fiscal years held
In US dollars, as EAGLE PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020FY2021FY2022
Salary$769,410$769,410$822,093$815,914$848,940
Bonus$0$0$0$0$0
Stock awards$5,681,970$2,599,120$3,485,757$4,293,836$9,011,197
Option awards$4,199,835$2,955,330$4,584,223$0$0
Non-equity incentive$654,000$1,538,800$554,750$1,338,700$636,705
Pension and deferred compensation$0$0$0$0$0
All other$19,241$21,017$22,610$23,071$23,735
Total$11,324,456$7,883,677$9,469,433$6,471,521$10,520,577

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: EAGLE PHARMACEUTICALS, INC. DEF 14A filed May 1, 2023, accession 0001104659-23-054338, and prior-year filings. Open the filing on EDGAR.

How this page was built: the EAGLE PHARMACEUTICALS, INC. filed document, accession 0001104659-23-054338. Every figure is read from that document and cited to the page and table it appears in. Filed May 1, 2023.

$11.3M
$7.9M
$9.5M
$6.5M
$10.5M
FY18
FY19
FY20
FY21
FY22
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
PSU60,400$3,075,568—
PSU104,500$3,054,535—
PSU25,900$1,318,828—
RSU34,800$1,017,204—
RSU29,150$852,055—
RSU15,325$447,950—
Option39,460—$59.79
Option2,858—$42.40

Per the Outstanding Equity Awards at Fiscal Year-End table in EAGLE PHARMACEUTICALS, INC.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

15 Form 4 lines since the FY2022 proxy (filed May 1, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2024-02-28Tax withholding—2,119$6.27460,621
2024-02-27Tax withholding—3,154$6.44462,740
2024-02-27Grant or award—12,950—465,894
2024-01-05Tax withholding—4,322$5.13541,125
2023-11-02Sale10b5-110,694$13.87545,447
2023-11-01Sale10b5-110,925$13.82556,141
2023-10-03Sale10b5-1710$15.11567,066
2023-10-03Sale10b5-110,024$14.41567,776

The 8 most recent of 15 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Change-in-control & termination

estimated payments EAGLE PHARMACEUTICALS discloses, by trigger · FY2022
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Involuntary termination without cause$2,122,350$7,825,651$34,163$9,982,164
Resignation for good reason, no change in control$2,122,350$7,825,651$34,163$9,982,164
Change in control and resignation for good reason$3,395,760$7,825,651$45,550$11,266,961
Disability$0$7,825,651$0$7,825,651
Change in control, no termination$0$7,825,651$0$7,825,651
Change in control and involuntary termination$3,395,760$7,825,651$45,550$11,266,961
Death$0$7,825,651$0$7,825,651

Per the Potential Payments Upon Termination or Change in Control table in EAGLE PHARMACEUTICALS, INC.'s FY2022 proxy. Estimates as the company printed them; a dash means it printed no figure.

EAGLE PHARMACEUTICALS’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Scott Tarriff · this pagePresident, Chief Executive Officer, Director$10,520,577
Michael MoranFormer Chief Commercial Officer$2,608,325
Brian CahillChief Financial Officer$2,493,347

Board service

EAGLE PHARMACEUTICALS board · FY2021–FY2022

How this board is paid

Company policy: EAGLE PHARMACEUTICALS pays directors a $65,000 cash retainer. As stated in EAGLE PHARMACEUTICALS's FY2022 proxy.

Committees

Strategic Clinical Development

The full EAGLE PHARMACEUTICALS compensation record

free company brief

This page is one person within EAGLE PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the EAGLE PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are EAGLE PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Scott Tarriff's compensation dossier · One-time report. No refunds.